PDB Short entry for 2P16 HEADER HYDROLASE 02-MAR-07 2P16 TITLE FACTOR XA IN COMPLEX WITH THE INHIBITOR APIXABAN (BMS-562247) AKA 1- TITLE 2 (4-METHOXYPHENYL)-7-OXO-6-(4-(2-OXO-1-PIPERIDINYL)PHENYL)-4,5,6,7- TITLE 3 TETRAHYDRO-1H-PYRAZOLO[3, 4-C]PYRIDINE-3-CARBOXAMIDE COMPND MOL_ID: 1; COMPND 2 MOLECULE: COAGULATION FACTOR X (EC 3.4.21.6) (STUART FACTOR) (STUART- COMPND 3 PROWER FACTOR); COMPND 4 CHAIN: A; COMPND 5 FRAGMENT: COAGULATION FACTOR X, HEAVY CHAIN; COMPND 6 SYNONYM: FACTOR XA HEAVY CHAIN, ACTIVATED FACTOR XA HEAVY CHAIN; COMPND 7 EC: 3.4.21.6; COMPND 8 MOL_ID: 2; COMPND 9 MOLECULE: COAGULATION FACTOR X (EC 3.4.21.6) (STUART FACTOR) (STUART- COMPND 10 PROWER FACTOR); COMPND 11 CHAIN: L; COMPND 12 FRAGMENT: COAGULATION FACTOR X, LIGHT CHAIN; COMPND 13 SYNONYM: FACTOR XA LIGHT CHAIN; COMPND 14 EC: 3.4.21.6 SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 MOL_ID: 2; SOURCE 6 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 7 ORGANISM_COMMON: HUMAN; SOURCE 8 ORGANISM_TAXID: 9606; SOURCE 9 OTHER_DETAILS: PROTEOLYTIC CLEAVAGE PRODUCT KEYWDS GLYCOPROTEIN, HYDROLASE, SERINE PROTEASE, PLASMA, BLOOD COAGULATION KEYWDS 2 FACTOR, PROTEIN INHIBITOR COMPLEX, CALCIUM-BINDING EXPDTA X-RAY DIFFRACTION AUTHOR R.ALEXANDER REVDAT 4 30-AUG-23 2P16 1 REMARK REVDAT 3 24-FEB-09 2P16 1 VERSN REVDAT 2 13-NOV-07 2P16 1 JRNL REVDAT 1 16-OCT-07 2P16 0 JRNL AUTH D.J.PINTO,M.J.ORWAT,S.KOCH,K.A.ROSSI,R.S.ALEXANDER, JRNL AUTH 2 A.SMALLWOOD,P.C.WONG,A.R.RENDINA,J.M.LUETTGEN,R.M.KNABB, JRNL AUTH 3 K.HE,B.XIN,R.R.WEXLER,P.Y.LAM JRNL TITL DISCOVERY OF JRNL TITL 2 1-(4-METHOXYPHENYL)-7-OXO-6-(4-(2-OXOPIPERIDIN-1-YL)PHENYL) JRNL TITL 3 -4,5,6,7-TETRAHYDRO- JRNL TITL 4 1H-PYRAZOLO[3,4-C]PYRIDINE-3-CARBOXAMIDE (APIXABAN, JRNL TITL 5 BMS-562247), A HIGHLY POTENT, SELECTIVE, EFFICACIOUS, AND JRNL TITL 6 ORALLY BIOAVAILABLE INHIBITOR OF BLOOD COAGULATION FACTOR JRNL TITL 7 XA. JRNL REF J.MED.CHEM. V. 50 5339 2007 JRNL REFN ISSN 0022-2623 JRNL PMID 17914785 JRNL DOI 10.1021/JM070245N REMARK 2 REMARK 2 RESOLUTION. 2.30 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.30 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 19.44 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 338510.230 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 96.8 REMARK 3 NUMBER OF REFLECTIONS : 14544 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.232 REMARK 3 R VALUE (WORKING SET) : 0.229 REMARK 3 FREE R VALUE : 0.277 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.900 REMARK 3 FREE R VALUE TEST SET COUNT : 854 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.009 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL WITH ALL DATA. REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.2590 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.2550 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.319 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 5.900 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 890 REMARK 3 ESTIMATED ERROR OF FREE R VALUE (NO CUTOFF) : 0.0110 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 15015 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 8 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.30 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.40 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 94.90 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 1645 REMARK 3 BIN R VALUE (WORKING SET) : 0.2530 REMARK 3 BIN FREE R VALUE : 0.3150 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 5.00 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 87 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.034 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2238 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 35 REMARK 3 SOLVENT ATOMS : 121 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 27.10 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 30.00 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -1.63000 REMARK 3 B22 (A**2) : -1.27000 REMARK 3 B33 (A**2) : 2.90000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.29 REMARK 3 ESD FROM SIGMAA (A) : 0.20 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.38 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.27 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.008 REMARK 3 BOND ANGLES (DEGREES) : 1.500 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 23.20 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.760 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.480 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 2.460 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 1.900 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 2.850 ; 2.500 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.41 REMARK 3 BSOL : 50.64 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.P REMARK 3 PARAMETER FILE 2 : DNA-RNA_REP.P REMARK 3 PARAMETER FILE 3 : WATER_REP.PAR REMARK 3 PARAMETER FILE 4 : ION.PARAM REMARK 3 PARAMETER FILE 5 : GG2.PAR REMARK 3 PARAMETER FILE 6 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : DNA-RNA.TOP REMARK 3 TOPOLOGY FILE 3 : WATER.TOP REMARK 3 TOPOLOGY FILE 4 : ION.TOP REMARK 3 TOPOLOGY FILE 5 : GG2.TOP REMARK 3 TOPOLOGY FILE 6 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2P16 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 09-MAR-07. REMARK 100 THE DEPOSITION ID IS D_1000041837. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 01-APR-02 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 5.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU RU200 REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.54 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : RIGAKU RAXIS IIC REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 (DENZO) REMARK 200 DATA SCALING SOFTWARE : HKL-2000 (SCALEPACK) REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 15116 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.300 REMARK 200 RESOLUTION RANGE LOW (A) : 19.440 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : NULL REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : NULL REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : NULL REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: EPMR REMARK 200 STARTING MODEL: PDB ENTRY 1FJS WITHOUT INHIBITOR AND SOLVENT REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 51.64 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.54 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 200 MM SODIUM ACETATE, 18% PEG6000, REMARK 280 VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K, PH 5.5 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 28.20000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 39.70000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 36.40000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 39.70000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 28.20000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 36.40000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 300 REMARK: BIOLOGICAL UNIT IS CONTAINED IN ASYMMETRIC UNIT REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, L REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 480 REMARK 480 ZERO OCCUPANCY ATOM REMARK 480 THE FOLLOWING RESIDUES HAVE ATOMS MODELED WITH ZERO REMARK 480 OCCUPANCY. THE LOCATION AND PROPERTIES OF THESE ATOMS REMARK 480 MAY NOT BE RELIABLE. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 480 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 480 M RES C SSEQI ATOMS REMARK 480 LYS A 62 CG CD CE NZ REMARK 480 ARG A 150 CG CD NE CZ NH1 NH2 REMARK 480 LYS A 223 CG CD CE NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ARG A 154 CB - CG - CD ANGL. DEV. = 18.7 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 24 109.66 -43.53 REMARK 500 ASN A 92 3.09 -67.57 REMARK 500 ARG A 115 -168.01 -167.81 REMARK 500 LEU L 88 -118.65 30.14 REMARK 500 GLN L 98 -113.06 -130.90 REMARK 500 LYS L 122 -52.75 -126.11 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CA A 301 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GG2 A 298 DBREF 2P16 A 16 244 UNP P00742 FA10_HUMAN 235 468 DBREF 2P16 L 87 138 UNP P00742 FA10_HUMAN 127 178 SEQRES 1 A 234 ILE VAL GLY GLY GLN GLU CYS LYS ASP GLY GLU CYS PRO SEQRES 2 A 234 TRP GLN ALA LEU LEU ILE ASN GLU GLU ASN GLU GLY PHE SEQRES 3 A 234 CYS GLY GLY THR ILE LEU SER GLU PHE TYR ILE LEU THR SEQRES 4 A 234 ALA ALA HIS CYS LEU TYR GLN ALA LYS ARG PHE LYS VAL SEQRES 5 A 234 ARG VAL GLY ASP ARG ASN THR GLU GLN GLU GLU GLY GLY SEQRES 6 A 234 GLU ALA VAL HIS GLU VAL GLU VAL VAL ILE LYS HIS ASN SEQRES 7 A 234 ARG PHE THR LYS GLU THR TYR ASP PHE ASP ILE ALA VAL SEQRES 8 A 234 LEU ARG LEU LYS THR PRO ILE THR PHE ARG MET ASN VAL SEQRES 9 A 234 ALA PRO ALA CYS LEU PRO GLU ARG ASP TRP ALA GLU SER SEQRES 10 A 234 THR LEU MET THR GLN LYS THR GLY ILE VAL SER GLY PHE SEQRES 11 A 234 GLY ARG THR HIS GLU LYS GLY ARG GLN SER THR ARG LEU SEQRES 12 A 234 LYS MET LEU GLU VAL PRO TYR VAL ASP ARG ASN SER CYS SEQRES 13 A 234 LYS LEU SER SER SER PHE ILE ILE THR GLN ASN MET PHE SEQRES 14 A 234 CYS ALA GLY TYR ASP THR LYS GLN GLU ASP ALA CYS GLN SEQRES 15 A 234 GLY ASP SER GLY GLY PRO HIS VAL THR ARG PHE LYS ASP SEQRES 16 A 234 THR TYR PHE VAL THR GLY ILE VAL SER TRP GLY GLU GLY SEQRES 17 A 234 CYS ALA ARG LYS GLY LYS TYR GLY ILE TYR THR LYS VAL SEQRES 18 A 234 THR ALA PHE LEU LYS TRP ILE ASP ARG SER MET LYS THR SEQRES 1 L 52 LYS LEU CYS SER LEU ASP ASN GLY ASP CYS ASP GLN PHE SEQRES 2 L 52 CYS HIS GLU GLU GLN ASN SER VAL VAL CYS SER CYS ALA SEQRES 3 L 52 ARG GLY TYR THR LEU ALA ASP ASN GLY LYS ALA CYS ILE SEQRES 4 L 52 PRO THR GLY PRO TYR PRO CYS GLY LYS GLN THR LEU GLU HET CA A 301 1 HET GG2 A 298 34 HETNAM CA CALCIUM ION HETNAM GG2 1-(4-METHOXYPHENYL)-7-OXO-6-[4-(2-OXOPIPERIDIN-1-YL) HETNAM 2 GG2 PHENYL]-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDINE- HETNAM 3 GG2 3-CARBOXAMIDE FORMUL 3 CA CA 2+ FORMUL 4 GG2 C25 H25 N5 O4 FORMUL 5 HOH *121(H2 O) HELIX 1 1 ALA A 55 GLN A 61 5 7 HELIX 2 2 GLU A 124A LEU A 131A 1 9 HELIX 3 3 ASP A 164 SER A 172 1 9 HELIX 4 4 PHE A 234 MET A 242 1 9 HELIX 5 5 LYS L 87 CYS L 96 5 10 SHEET 1 A 7 GLN A 20 GLU A 21 0 SHEET 2 A 7 LYS A 156 PRO A 161 -1 O MET A 157 N GLN A 20 SHEET 3 A 7 THR A 135 GLY A 140 -1 N VAL A 138 O LEU A 158 SHEET 4 A 7 PRO A 198 PHE A 203 -1 O VAL A 200 N ILE A 137 SHEET 5 A 7 THR A 206 TRP A 215 -1 O THR A 210 N HIS A 199 SHEET 6 A 7 GLY A 226 LYS A 230 -1 O ILE A 227 N TRP A 215 SHEET 7 A 7 MET A 180 ALA A 183 -1 N PHE A 181 O TYR A 228 SHEET 1 B 7 GLN A 30 ILE A 34 0 SHEET 2 B 7 GLY A 40 ILE A 46 -1 O GLY A 44 N ALA A 31 SHEET 3 B 7 TYR A 51 THR A 54 -1 O LEU A 53 N THR A 45 SHEET 4 B 7 ALA A 104 LEU A 108 -1 O LEU A 106 N ILE A 52 SHEET 5 B 7 ALA A 81 LYS A 90 -1 N VAL A 87 O ARG A 107 SHEET 6 B 7 LYS A 65 VAL A 68 -1 N VAL A 66 O HIS A 83 SHEET 7 B 7 GLN A 30 ILE A 34 -1 N LEU A 32 O ARG A 67 SHEET 1 C 2 PHE L 99 GLU L 103 0 SHEET 2 C 2 SER L 106 SER L 110 -1 O VAL L 108 N HIS L 101 SHEET 1 D 2 TYR L 115 LEU L 117 0 SHEET 2 D 2 CYS L 124 PRO L 126 -1 O ILE L 125 N THR L 116 SSBOND 1 CYS A 22 CYS A 27 1555 1555 2.60 SSBOND 2 CYS A 42 CYS A 58 1555 1555 2.70 SSBOND 3 CYS A 122 CYS L 132 1555 1555 2.43 SSBOND 4 CYS A 168 CYS A 182 1555 1555 2.72 SSBOND 5 CYS A 191 CYS A 220 1555 1555 2.56 SSBOND 6 CYS L 89 CYS L 100 1555 1555 2.54 SSBOND 7 CYS L 96 CYS L 109 1555 1555 2.48 SSBOND 8 CYS L 111 CYS L 124 1555 1555 2.52 SITE 1 AC1 5 ASP A 70 ASN A 72 GLN A 75 GLU A 77 SITE 2 AC1 5 GLU A 80 SITE 1 AC2 17 GLU A 97 THR A 98 GLU A 146 PHE A 174 SITE 2 AC2 17 ASP A 189 ALA A 190 CYS A 191 GLN A 192 SITE 3 AC2 17 SER A 195 VAL A 213 TRP A 215 GLY A 216 SITE 4 AC2 17 GLY A 218 CYS A 220 GLY A 226 HOH A 370 SITE 5 AC2 17 HOH A 395 CRYST1 56.400 72.800 79.400 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.017730 0.000000 0.000000 0.00000 SCALE2 0.000000 0.013736 0.000000 0.00000 SCALE3 0.000000 0.000000 0.012594 0.00000